patients considering the impact of surgical interventions on their sexual health. Mark D. Tyson, M.D. Mitchell R. Humphreys, M.D. Department of Urology Mayo Clinic College of Medicine Phoenix, AZ References 1. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326. 2. Arrington R, CoFranscesco J, Wu AW. Questionnaires to measure sexual quality of life. Qual Life Res. 2004;13:16431658. 3. Elshal AM, Elmansy HM, Elkoushy MA, Elhialali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. Urology. 2012;80:1098-1104.
Re: Wolder et al.: Who Really Benefits From Nephron-sparing Surgery? (Urology 2014;84: 860-868) TO THE EDITOR:
We read with great interest the article recently published by Wolder et al.1 The authors studied in adults with unilateral renal cancer the influence of estimated baseline glomerular filtration rate (eGFR) on renal function outcome after nephrectomy or nephron-sparing surgery (NSS). They concluded that only patients with baseline
chronic kidney disease (CKD) stage II (eGFR between 60 and 89 mL/min/1.73 m2) might benefit from NSS as they demonstrated a decreased risk of developing severe renal impairment. We made a similar study on our small cohort of children with unilateral renal tumor (URT; Fig. 1). We assumed that NSS should be considered beneficial if this surgical approach may prevent, at follow-up, a renal dysfunction defined as eGFR
Re: Wolder et al.: Who Really Benefits From Nephron-sparing Surgery? (Urology 2014;84: 860-868) TO THE EDITOR:
We read with great interest the article recently published by Wolder et al.1 The authors studied in adults with unilateral renal cancer the influence of estimated baseline glomerular filtration rate (eGFR) on renal function outcome after nephrectomy or nephron-sparing surgery (NSS). They concluded that only patients with baseline
chronic kidney disease (CKD) stage II (eGFR between 60 and 89 mL/min/1.73 m2) might benefit from NSS as they demonstrated a decreased risk of developing severe renal impairment. We made a similar study on our small cohort of children with unilateral renal tumor (URT; Fig. 1). We assumed that NSS should be considered beneficial if this surgical approach may prevent, at follow-up, a renal dysfunction defined as eGFR
